Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

about

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

Item

http://www.wikidata.org/entity/Q52740718

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@en

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@nl

type

Item

label

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@en

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@nl

prefLabel

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@en

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@nl

P1476

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

@en

P2093

Shekoufeh Nikfar

http://www.w3.org/2001/XMLSchema#string

Shilan Mozaffari

http://www.w3.org/2001/XMLSchema#string

P2860

Evolving paradigms in the treatment of opioid-induced bowel dysfunction

Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

Treatment of opioid-induced gut dysfunction

Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies

Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.

Advances in pharmacotherapy for opioid-induced constipation - a systematic review.

Incidence, prevalence, and management of opioid bowel dysfunction.

Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.

P304

235-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/13543784.2018.1420778

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mohammad Abdollahi

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29266973

http://www.w3.org/2001/XMLSchema#string

P921

opioid